Ask AI
Key Studies in GI Malignancies From ESMO 2025

CME

Key Studies in Gastrointestinal Malignancies: Independent Conference Coverage of the ESMO 2025 Congress

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: December 29, 2025

Expiration: June 28, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Tabernero J, Al-Batran S-E, Wainberg ZA, et al. Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma. Presented at the 2025 European Society of Medical Oncology Congress. Abstr LBA81.
  2. Janjigian YY, Al-Batran S-E, Wainberg ZA, et al. Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).  Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA5.
  3. Janjigian YY, Al-Batran S-E, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Eng J Med. 2025;393:217-230.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. v.4.2025. nccn.org. Accessed December 17, 2025.
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: gastric cancer. v.3.2025. nccn.org. Accessed December 17, 2025.
  6. Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948-1957.
  7. Janjigian YY, Rha SY, Oh D, et al. Domvanalimab (dom), zimberelimab (zim), and FOLFOX in first-line (1L) advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJ/EAC): 26-month update from EDGE-Gastric, arm A1. Presented at the 2025 European Society of Medical Oncology Congress. Abstr 2112MO.
  8. Janjigian YY, Oh D-Y, Pelster M, et al. Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. Nat Med. 2025;31:4274-4280.
  9. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.
  10. Rha SY, Oh D-Y, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181-1195.
  11. Rha SY, Cid RP, Montes AF, et al. Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase 3 study results. Presented at the 2025 European Society of Medical Oncology Congress. Abstr LBA10.
  12. Wainberg ZA, Kang Y-K, Lee K-W, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024;27:558-570.
  13. Drizyte-Miller K, Talabi T, Somasundaram K, et al. KRAS: the Achilles' heel of pancreas cancer biology. J Clin Invest. 2025;135: e191939.
  14. Xiong A, Zhou C, Zhang Y, et al. KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: A phase I trial. Presented at the 2025 European Society of Medical Oncology Congress. Abstr 915O.
  15. Wang L, Jiang K, Li W, et al. HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: a phase Ib/II study. Presented at the 2025 European Society of Medical Oncology Congress. Abstr 2215O.
  16. Desai J, Markman B, Millward M, et al. Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors. Presented at the 2025 European Society of Medical Oncology Congress. Abstr 916O.
  17. Tie J, Wang Y, Loree JM, et al. ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup Study of AGITG and CCTG). Presented at the 2025 European Society of Medical Oncology Congress. Abstr LBA9.
  18. Tie J, Cohen JD, Phil M, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Eng J Med. 2022;386:2261-2272.